CS Diagnostics Enlists Lachman Consultants to Secure FDA Approval for Novel Cancer Treatment Hydrogel
Key Insights
CS Diagnostics Corp. (search) (OTCQB:CSDX) has appointed Lachman Consultants (search) to navigate the FDA approval process for its innovative CS-Protect Hydrogel (search), an organ spacer technology for cancer (search) radiotherapy treatments.
The CS-Protect Hydrogel (search) offers significant advantages over previous products, including enhanced versatility for multiple pathologies, ready-to-use application, and reduced contamination risks during cancer (search) treatment procedures.
The company anticipates FDA approval within 3-4 months and projects production to begin in Q1 2026, with executives noting that a predecessor technology was acquired by Boston Scientific for $500 million.
CS Diagnostics Corp. (search) (OTCQB:CSDX) has appointed Lachman Consultants (search) to lead regulatory efforts for FDA approval of its CS-Protect Hydrogel (search), an innovative tissue spacer technology designed to improve radiation treatments for cancer (search) patients.
The Wyoming-based company announced the strategic partnership on March 12, highlighting Lachman Consultants (search)' extensive experience in regulatory affairs and compliance services for pharmaceutical and medical device industries since 1978. The consultancy will provide specialized expertise to navigate the complex FDA approval process for the novel hydrogel technology.
Advanced Organ Protection Technology
CS-Protect Hydrogel (search) functions as an organ spacer medical device that creates separation between critical organs and targeted tissue during radiation therapy. This separation helps minimize radiation exposure to healthy tissues while allowing for more precise treatment of cancerous areas.
According to company officials, the hydrogel represents a significant advancement over previous technologies in the field. "CS-Protect Hydrogel (search) is more versatile and can be used in other pathologies beyond current applications," the company stated in its announcement. The product features advanced molecular structure and improved chemical and physical properties that enhance its medical applications.
The company anticipates a relatively swift approval timeline of 3-4 months for the U.S. market, following the completion of required testing procedures.
Clinical Advantages and Safety Features
Thomas Fahrhoefer, President of the Board at CS Diagnostics, emphasized the product's safety profile and ease of use: "The easy application of the CS-Protect Hydrogel (search) being a ready-to-use product after removal from sterile packaging and unrequired further work steps eliminates any risk of contamination due to preparation and assembly."
This ready-to-use design removes potential hygienic risks within treatment rooms and eliminates concerns about improper mixing or preparation that could lead to missed treatments or suboptimal outcomes for patients undergoing radiation therapy.
Market Potential and Production Timeline
The company has positioned CS-Protect Hydrogel (search) as a potentially valuable asset in the medical device market. Mohammad EsSayed, Vice President of the Board, noted that a predecessor product was acquired by Boston Scientific for $500 million, suggesting significant market potential for the new technology.
"We project the start of the production of CS-Protect Hydrogel (search) in the U.S. market towards the first quarter of 2026," EsSayed stated, outlining the company's timeline following anticipated FDA approval.
Radiation Therapy Context
Radiation therapy remains a cornerstone of cancer (search) treatment, with an estimated 50-60% of cancer patients receiving this therapy during their treatment course. Protecting healthy tissues during these procedures is critical for reducing side effects and improving patient outcomes.
Hydrogel spacers have emerged as important tools in radiation oncology, particularly for protecting organs adjacent to treatment sites. The technology has shown particular value in prostate cancer (search) treatment, where hydrogel spacers can create separation between the prostate and rectum, reducing rectal toxicity during radiation therapy.
Corporate Strategy
As a publicly traded company on the OTCQB market, CS Diagnostics is positioning this product development as part of a broader strategy for growth. The company aims to provide U.S. investors with access to what it describes as a "high-growth opportunity" in the medical device sector.
The partnership with Lachman Consultants (search) represents a significant step in the company's regulatory strategy. Lachman brings expertise in compliance, regulatory affairs, and technical services across pharmaceutical, biotechnology, biologics, cell and gene therapy, and medical device industries.
CS Diagnostics has indicated that further information about the CS-Protect Hydrogel (search) technology is available on the company's website, with additional details expected as the approval process advances.